Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $142.04 USD
Change Today -2.29 / -1.59%
Volume 831.7K
BDX On Other Exchanges
New York
As of 4:15 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

becton dickinson and co (BDX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/15 - $149.98
52 Week Low
05/1/14 - $111.07
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BECTON DICKINSON AND CO (BDX)

becton dickinson and co (BDX) Related Businessweek News

View More BusinessWeek News

becton dickinson and co (BDX) Details

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company’s BD Medical segment produces medical devices, such as needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for use in the treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; and generic prefilled injectables. Its BD Diagnostics segment provides products for the collection and transportation of diagnostics specimens; and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections, and cancers. This segment’s products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood and tuberculosis culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems; rapid diagnostic assays; microbiology laboratory automation; and plated media. The company’s BD Medical segment offers research and clinical tools, such as fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. It also develops technologies that address biological analysis protocols, including library preparation of next generation sequencing and genotyping applications. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.

30,619 Employees
Last Reported Date: 11/26/14
Founded in 1897

becton dickinson and co (BDX) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $985.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $690.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $721.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $900.8K
Executive Vice President
Total Annual Compensation: $605.7K
Compensation as of Fiscal Year 2014.

becton dickinson and co (BDX) Key Developments

Retractable Technologies Announces U.S. Supreme Court Decision on Denial of Writ of Certiorari

Retractable Technologies Inc. announced that on April 20, 2015, the Supreme Court of the United States denied the petition for a writ of certiorari by Becton, Dickinson and Company (BD) relating to its Rule 60(b) motion in the portion of Retractable's case against BD addressing patent infringement claims. The patent claims were severed from Retractable's other claims against BD in 2008. The other portion of the case in which the District Court granted Retractable a final judgment for $352 million plus other relief is not directly affected by the recent Supreme Court ruling.

Becton, Dickinson Reportedly Looks To Sell Respiratory Device Unit

Becton, Dickinson and Company (NYSE:BDX) is reportedly planning to sell its respiratory-devices unit according to people with knowledge of the matter. Becton, Dickinson is looking to sell unwanted assets following its acquisition of CareFusion Corp. “We’re conducting a strategic review of all of our businesses but haven’t made any decisions,” said Kristen Cardillo, a spokeswoman for Becton Dickinson.

Becton, Dickinson and Company and CareFusion Corporation Receives Clearance from the European Commission for the Pending Acquisition

Becton, Dickinson and Company and CareFusion Corporation announced that the companies have received clearance from the European Commission under the EU Merger Regulation for the pending acquisition of CareFusion by BD. The proposed acquisition has now received all necessary regulatory approvals. The proposed acquisition, which has been approved by CareFusion shareholders, remains subject to customary closing conditions. BD and CareFusion currently expect the proposed acquisition to close on March 17, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDX:US $142.04 USD -2.29

BDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,934 JPY -14.50
Avago Technologies Ltd $120.15 USD +0.65
Boston Scientific Corp $17.98 USD -0.36
Mylan NV $71.72 USD -4.34
Stryker Corp $94.63 USD -2.27
View Industry Companies

Industry Analysis


Industry Average

Valuation BDX Industry Range
Price/Earnings 24.8x
Price/Sales 3.3x
Price/Book 5.5x
Price/Cash Flow 26.2x
TEV/Sales 1.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BECTON DICKINSON AND CO, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at